Skip to Content

  • Search

View Additional Section Content

LPT 112515 - A Randomized, Phase III, Open-label, Study of Lapatinib plus Trastuzumab versus Trastuzumab as Continued HER2 Suppression Therapy after Completion of First or Second Line Trastuzumab plus Chemotherapy in Subjects with HER2 Positive Metastatic Breast Cancer.

Clinical Trial Categories

  • Breast Cancer
Contact
The Rosenfeld Cancer Center at 215-481-2402

Location

  • The Rosenfeld Cancer Center

Find a Physician
Search Our Directory

215-481-MEDI

Schedule a Test
Request an Appointment

215-481-EXAM

Clinical Trials Details